Endometrial stromal sarcomas (ESS) are rare endometrial tumours arising from stroma of endometrium i.e. connective tissue of endometrium rather than glands. Usually a pre-operative diagnosis is difficult. Total abdominal hysterectomy with bilateral salpingo-oophorectomy is main line of treatment. Adjuvant hormone therapy in the form of progesterones, GnRH analogues, aromatase inhibitors are effective for prevention of recurrences as these tumours are invariably positive for oestrogen & progesterone receptors. Surgical excision, radiotherapy, hormone therapy are recommended for recurrences. We report a 52 yrs widow with undifferentiated endometrial stromal sarcoma weighing 3.75 kg with a short history of 3 months diagnosed only after histopathology.
INTRODUCTION
Endometrial stromal sarcomas (ESS) are very rare malignant tumours that make around 0.2% of all uterine malignancies. They resemble endometrial stromal cells in the proliferative stage. The annual incidence of ESS is 1-2 per million women. Compared to other uterine malignancies, ESS affects younger women and the mean age is 42 to 58 years. 1 They account for less than 10% of the uterine mesenchymal neoplasm and 10 to 25% of affected women are premenopausal. ESS is an indolent tumour with local recurrences and distant metastasis can occur even 20 years after initial diagnosis.
CASE REPORT
A 52 years old widow, postmenopausal for the last 2 years, P1L1A1 with previous one caesarean presented with symptoms of abdominal distension, pain lower abdomen, increased frequency of micturition, decreased appetite and generalized weakness for 3 months and constipation for one month. On general physical examination, she was poorly nourished with moderate anemia.
Abdominal examination revealed a solid mass of 34 week size, superiorly reaching up to epigastrium, laterally to the flanks. Lower edge could not be reached. It was dull on percussion and no shifting dullness was present. On per vaginal examination, solid firm mass felt in posterior fornix. Uterus could not be felt separately from the mass. Cervix was pin pointed and placed anteriorly. Per rectal examination revealed rectal mucosa free, mass felt anteriorly.
Her blood investigations revealed anemia, with Hb 8gm%.Liver function, Kidney function tests were within normal limits. CA125 was 144.06 IU/l. X ray chest normal. Ultrasound showed 23×17 cm solid mass showing heterogenous echotexture arising from pelvis and extending into abdomen. Uterus could not be visualized separately. CT scan showed heterogenous enhancing mass in pelvis measuring 14×22×27 cm. Uterus and adnexa could not be separately defined from this mass. Mass was displacing the gut loops and causing Department of Obstetrics & Gynaecology, Govt. Medical College, Amritsar, Punjab, India compression of urinary bladder. FNAC showed malignant mesenchymal tumour. Patient was built up for surgery, counselling done. Thinking it to be an ovarian mass patient was taken for exploratory laparotomy.
Per operatively large, solid, highly vascular, lobulated mass with irregular margins and areas of necrosis, size about 30×25 cm, extending up to xiphisternum, laterally extending upto flanks, inferiorly reaching pelvis was seen. The posterior surface of tumour was adherent to gut and omentum. Peritoneal washings taken. Inspection of abdominal cavity was done for locating any possible sites of metastasis. Pelvic lymph nodes were palpated and not found to be enlarged. Omentum was carefully inspected and no gross pathology was found. Posterior surface of uterus & right ovary was normally looking (Figure 1 On gross pathological examination, specimen measured 29×24×9 cm & weighed 3.75 kg, large bulbous nodular irregular mass involving the left anterolateral uterine wall. On cutting multiple, circumscribed, grey white solid nodular areas were seen in the wall of the uterus. Both the tubes and ovaries were identified, were normal looking.
Microscopically, the wall of the uterus showed round to oval spindle shaped cells arranged in nodules & sheets. Cells having pleomorphic bizarre nuclei with prominent nucleoli were seen with areas of necrosis. Mitotic activity was increased. Tumour was infiltrating into the cervix. Both ovaries were unremarkable. There was no infiltration of the omentum by the tumour tissue. Features were suggestive of endometrial stromal sarcomaUndifferentiated type (UES). Post-operative patient was given 3 courses of radiotherapy. On follow up visit after 6 months, she is fine. 
DISCUSSION
The origin & biology of tumour is poorly understood. Its seen that a recurrent chromosomal translocation t(7;17)(p15;q21) occurs in ESS. Even normal endometrial stromal cells express this fusion gene showing that a prosurvival gene in normal endometrium somehow subverted to become proneoplastic. 2 The exposure to unopposed oestrogens & polycystic ovarian disease also have some role in pathogenesis. 3 Our patient had only one child & took some treatment of infertility irregularly but she has no record of type of treatment. In this classification, the differentiation between low grade & undifferentiated tumours is not made not on mitotic count but on the basis of nuclear pleomorphism & necrosis.
Our patient had undifferentiated endometrial stromal sarcoma.
The clinical presentation of ESS is abnormal uterine bleeding, pain abdomen, may be asymptomatic, (25%). Our patient was postmenopausal, presented with abdominal enlargement, pressure symptoms & pain abdomen as the tumour was growing outwards from uterine wall & was measuring 3.75kg.U/S is not reliable for diagnosis. MRI may be useful by presence of bands of low intensity signals within areas of myometrial invasion. CD 10 a cell surface neutral endopeptidase has been shown as positive in ESS differentiating it from leiomyoma which is negative for CD 10. 4 ESS is always positive for oestrogen & progesterone receptors.
Standard surgical treatment is total abdominal hysterectomy with bilateral salpingooophorectomy. Only postoperative observation is required for stage 1. Postoperative HRT is contraindicated as the tumour is oestrogen & progesterone receptor positive. 5 For stage II to IV/recurrence/unresectable tumour, post-operative hormone treatment or radiotherapy is indicated.
CONCLUSION
ESS is a rare tumour, optimal treatment regimens are difficult to formulate as randomised clinical trials are not conducted. Late recurrences even after 20 years are seen so it needs long term follow up.
